Long-Term Benefit Observed With Sotorasib in KRAS-Mutant Non-Small Cell Lung Cancer
The 2-year overall survival rate was 32.5%.
The 2-year overall survival rate was 32.5%.
A meta-analysis revealed inferior responses, progression-free survival, and overall survival in patients exposed to antibiotics.
Data suggest nivolumab plus ipilimumab provides a long-term survival benefit in patients with unresectable malignant pleural mesothelioma.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.